CLINICAL DIVISION OF IUPHAR

Meeting of the Clinical Division of IUPHAR
Thursday, July the 6th 2006 from 14h30 to 17h30
15th World Congress of Pharmacology, Beijing, China

Present:
Patrick du Souich (Canada) (President)
Kim Brosen (Denmark) (Secretary)
Petra Thürmann (Germany) (Treasurer)
Don J. Birkett (Vice-President)(Australia)
Kalle Hoppu (Finland)
Gilberto Castaneda (Mexico)
Shinichi Kobayashi (Japan)
Wim du Ploy (South Africa)
David Webb (United Kingdom)
Emilio J Sanz (Spain)
Sue Duckles (United States) (President IUPHAR)
Salvatore J. Enna (United States) (Secretary General IUPHAR)
Jaime Kapitulnik (Israel) (Chairman Section Drug Metabolism)
Madlen Gazarian (Australia)
Cai-Li Zhang (China)
Anne Zajieck (United States)

Apologies:
Folke Sjöqvist (Sweden)
Fan-Dian ZENG (China)
Hyung-Keun Roh (South Korea)
Mohammed Ibrahim A. Ibrahim (Egypt)
Darrell Abernethy (USA)
Luigi Cubbeddu (Venezuela)
Emilio Perucca (Italy)

1. The agenda was adopted
2. Patrick du Souich gave a summary of the president’s written report. The report was accepted.
3. The secretary had nothing to report
4. Petra Thürmann reported on the financial situation of the Clinical Division with emphasis on the transferral to a new bank account taking over from the previous treasurer
5. There was a discussion about objectives and futures projects. David Webb asked about the right to use the name IUPHAR as a brand for specific meetings and activities, and Sue Duckles pointed out, that there is big freedom to use the IUPHAR brand as long as the scientific quality and integrity of such activities is indisputable.
6. Kalle Hoppu gave a comprehensive report on the Section of Paediatric Clinical Pharmacology, which has been very active recently. There had been meetings in March in Baltimore, in June in Stockholm and the week before the World Congress in Shanghai. The group had produced
position paper entitled “International Alliance for Better Medicines for Children” on the need to improve the use of medicines in children in the developing countries. A discussion followed on where to send such a position paper. The following agreements were reached:

Sue Duckles emphasized that IUPHAR fully backs up the initiative “International Alliance for Better Medicines for Children” and the activities on paediatric pharmacology.

A teaching platform might be the most urgent task and IUPHAR can provide the Website and expertise for its use.

The Division will cover some of the costs arising from a meeting with WHO next autumn. Kalle Hoppu will make a concrete proposal to foster the International Alliance for Better Medicines for Children with a budget and the Division and IUPHAR will seek financial support (ICSU might be a source).

7. Emilio J Sanz reported on the Drug utilisation and pharmacoepidemiology section. The plans are to organize teaching programmes in lesser developed countries. He will submit a concrete proposal to the Division.

8. Lars Gustafsson (Sweden) has agreed to lead the section on Clinical Pharmacology in lesser developed countries.

9. Gilberto Castaneda reported on the Latin-American network for clinical pharmacology. There are two main problems in South America: Physicians are busy treating patients and they don’t speak or write English.

10. Patrick du Souich reported on CPT 2008 in Quebec and Kim Brøsen reported on WorldPharma2010 in Copenhagen. Strategies to attract registrations were discussed.

11. Wim du Plooy reported on the ICSU Health and Well Being Initiative. He explained the aims and goals and the Division gave its support to the continued work. He will represent IUPHAR in the ICSU Health and Well Being Initiative.

12. Jaime Kapitulnik gave a short report on the Drug Metabolism Section and offered to work more closely with the Division because the interests overlap. It was agreed that the Division and Section will communicate more frequently and send the reports and minutes of meetings.

13. David Webb reported on an initiative to make a questionnaire that would enable him to get an overview on clinical pharmacology in individual countries worldwide. The initiative is a follow up on his letter in the Lancet previously this year in which he described the problematic situation for clinical pharmacology in the UK.

14. Next meeting will be during the CPT in Quebec in 2008.

Kim Brøsen